Join us with our two guests:
Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology.
Both Dr. Pletan and Gaudriault will introduce and discuss
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837.
DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections
|